We recently published a list of 10 Best Performing Long Term Stocks So Far in 2025. In this article, we are going to take a look at where Altria Group, Inc. (NYSE:MO) stands against other best performing long term stocks so far in 2025. Consumer morale fell more drastically than expected in April, owing to […]

We recently published a list of 10 Best Performing Long Term Stocks So Far in 2025. In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against other best performing long term stocks so far in 2025. Consumer morale fell more drastically than expected in April, owing to […]

We recently published a list of Jim Cramer’s List of 16 Stocks to Buy Right Now. In this article, we are going to take a look at where The Coca-Cola Company (NYSE:KO) stands against other stocks on Jim Cramer’s list to buy right now. On Monday, April 14th, Jim Cramer opened the Mad Money episode with a […]

We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Helmerich & Payne, Inc. (NYSE:HP) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid […]

We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Clarivate Plc (NYSE:CLVT) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing concerns […]

We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Charles River Laboratories International, Inc. (NYSE:CRL) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide […]

The stock fell as much as 20%, dragging industry peers Humana and CVS lower as well.

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It will report its Q1 2025 earnings on April 15. Wall Street analysts expect the company to post EPS of $2.59, down from $2.71 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $21.60 billion, up from $21.38 billion a year earlier. Don't Miss: Deloitte's fastest-growing software company partners with Am

Billionaire hedge-fund manager Bill Ackman disclosed a nearly 20% stake in rental-car company Hertz on Thursday as he laid out his bullish reasoning behind the bet. In a social-media post on X, Ackman said the current tariff environment helps Hertz, which he described as part of an oligopoly where Enterprise, Avis and Hertz control nearly 95% of the U.S. market. Driving his rationale: “Improving industry structure and more rational competitive behavior,” and fixing a recent misstep when Hertz acquired a large fleet of electric vehicles, Ackman wrote.

Although the revenue and EPS for Netflix (NFLX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.